CN105050585A - 稳定的葡萄糖激酶活化剂组合物 - Google Patents

稳定的葡萄糖激酶活化剂组合物 Download PDF

Info

Publication number
CN105050585A
CN105050585A CN201480011647.2A CN201480011647A CN105050585A CN 105050585 A CN105050585 A CN 105050585A CN 201480011647 A CN201480011647 A CN 201480011647A CN 105050585 A CN105050585 A CN 105050585A
Authority
CN
China
Prior art keywords
cyclohexyl
acetic acid
propoxy
trans
ureido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480011647.2A
Other languages
English (en)
Chinese (zh)
Inventor
Y·莫
M·G·戴德希亚
A·切特里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Publication of CN105050585A publication Critical patent/CN105050585A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480011647.2A 2013-03-04 2014-02-28 稳定的葡萄糖激酶活化剂组合物 Pending CN105050585A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772022P 2013-03-04 2013-03-04
US61/772,022 2013-03-04
PCT/US2014/019349 WO2014137797A2 (en) 2013-03-04 2014-02-28 Stable glucokinase activator compositions

Publications (1)

Publication Number Publication Date
CN105050585A true CN105050585A (zh) 2015-11-11

Family

ID=50424705

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480011647.2A Pending CN105050585A (zh) 2013-03-04 2014-02-28 稳定的葡萄糖激酶活化剂组合物

Country Status (11)

Country Link
US (1) US20160015638A1 (https=)
EP (1) EP2964198A2 (https=)
JP (1) JP6441828B2 (https=)
KR (1) KR20150123838A (https=)
CN (1) CN105050585A (https=)
AU (1) AU2014226290B2 (https=)
CA (1) CA2903433A1 (https=)
HK (1) HK1213780A1 (https=)
IL (1) IL240735A0 (https=)
MX (1) MX2015011109A (https=)
WO (1) WO2014137797A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109646404A (zh) * 2016-12-15 2019-04-19 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
CN116194442A (zh) * 2020-06-08 2023-05-30 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2576524T (pt) 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo
HK1202458A1 (en) 2012-05-17 2015-10-02 Vtv治疗有限责任公司 Glucokinase activator compositions for the treatment of diabetes
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US11857536B2 (en) 2020-06-04 2024-01-02 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CA3185831A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CN116056760A (zh) * 2020-06-08 2023-05-02 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
KR20240084229A (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499299A2 (en) * 1991-01-25 1992-08-19 NanoSystems L.L.C. Surface modified drug nanoparticles
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2008079787A2 (en) * 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
CN102497858A (zh) * 2009-06-19 2012-06-13 纳米模型匈牙利有限公司 纳米颗粒替米沙坦组合物及其制备方法
CN102516240A (zh) * 2004-01-06 2012-06-27 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
CN102802609A (zh) * 2009-06-18 2012-11-28 雅培制药有限公司 稳定的纳米颗粒药物悬浮液

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1429731B1 (en) * 2001-09-19 2007-01-03 Elan Pharma International Limited Nanoparticulate insulin formulations
US20040018242A1 (en) * 2002-05-06 2004-01-29 Elan Pharma International Ltd. Nanoparticulate nystatin formulations
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
CA2488617A1 (en) * 2002-06-10 2003-12-18 Eugene R. Cooper Nanoparticulate sterol formulations and sterol combinations
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
KR20070118224A (ko) * 2005-01-06 2007-12-14 엘란 파마 인터내셔널 리미티드 나노입자형 칸데사르탄 제제
MX2007010394A (es) * 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
CN101198316A (zh) * 2005-03-17 2008-06-11 伊兰制药国际有限公司 纳米微粒双膦酸盐组合物
US20060210638A1 (en) * 2005-03-17 2006-09-21 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
KR20080008403A (ko) * 2005-05-10 2008-01-23 엘란 파마 인터내셔널 리미티드 나노입자형 클로피도그렐 제제
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
ES2341996T3 (es) * 2005-06-03 2010-06-30 Elan Pharma International Limited Formulaciones de mesilato de imatinib en forma de manoparticulas.
BRPI0611075A2 (pt) * 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
EP1898882B1 (en) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanoparticulate ebastine formulations
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
JP2009538927A (ja) * 2006-05-30 2009-11-12 エラン ファーマ インターナショナル，リミティド ナノ粒子状のポサコナゾール製剤
AU2007325628A1 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US20090028680A1 (en) * 2007-07-27 2009-01-29 Kling Troy L Intermediate apparatus for towing utility vehicles
BRPI0912802A2 (pt) * 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
US8054567B2 (en) * 2008-07-23 2011-11-08 Hitachi High-Technologies Corporation Method for measuring write/read width of a composite magnetic head and a measuring device using the method
PT2576524T (pt) * 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499299A2 (en) * 1991-01-25 1992-08-19 NanoSystems L.L.C. Surface modified drug nanoparticles
CN102516240A (zh) * 2004-01-06 2012-06-27 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2008079787A2 (en) * 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
CN102802609A (zh) * 2009-06-18 2012-11-28 雅培制药有限公司 稳定的纳米颗粒药物悬浮液
CN102497858A (zh) * 2009-06-19 2012-06-13 纳米模型匈牙利有限公司 纳米颗粒替米沙坦组合物及其制备方法
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109646404A (zh) * 2016-12-15 2019-04-19 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
CN109674752A (zh) * 2016-12-15 2019-04-26 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
US11266630B2 (en) 2016-12-15 2022-03-08 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor
CN109646404B (zh) * 2016-12-15 2022-10-04 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
CN109674752B (zh) * 2016-12-15 2022-10-11 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
CN116194442A (zh) * 2020-06-08 2023-05-30 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途

Also Published As

Publication number Publication date
JP2016513625A (ja) 2016-05-16
MX2015011109A (es) 2015-11-16
KR20150123838A (ko) 2015-11-04
AU2014226290B2 (en) 2018-11-15
WO2014137797A3 (en) 2014-10-30
CA2903433A1 (en) 2014-09-12
EP2964198A2 (en) 2016-01-13
US20160015638A1 (en) 2016-01-21
WO2014137797A2 (en) 2014-09-12
JP6441828B2 (ja) 2018-12-19
HK1213780A1 (zh) 2016-07-15
AU2014226290A1 (en) 2015-10-08
IL240735A0 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
CN105050585A (zh) 稳定的葡萄糖激酶活化剂组合物
Gao et al. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs
EP3556354B1 (en) Oral preparation of glucokinase activator and preparation method therefor
US20220233701A1 (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
CN100560067C (zh) 盐酸决奈达隆口服药物组合物及其制备方法
US20230321246A1 (en) High-strength oral taxane compositions and methods
CN101600419A (zh) 含有瑞伐拉赞的固体分散体以及其制备方法
KR20080002689A (ko) 세팔로스포린을 함유하는 나노미립자 및 조절 방출 조성물
US20240207239A1 (en) Composition and preparation method therefor
EP2117511A2 (en) Pharmaceutical formulation comprising neurokinin antagonist
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
CN102908305B (zh) 一种含有盐酸决奈达隆的口服固体药物组合物及其制备方法
CN109394685B (zh) 一种vegfr抑制剂的药物组合物及其制备方法
EP3305282A2 (en) Composition of pranlukast-containing solid preparation with improved bioavailability and method for preparing same
CN101287453A (zh) 包含头孢菌素的毫微粒和控制释放组合物
US20250064798A1 (en) Vilazodone composition, pharmaceutical preparation thereof, preparation therefor, and use thereof
CN116687961A (zh) 一种含有兰索拉唑及碳酸氢钠的干混悬剂及其制备方法
CN118892469A (zh) 一种依折麦布和瑞舒伐他汀钙制剂组合物
CN119454591A (zh) 一种哒嗪类衍生物的纳米晶颗粒、组合物及其制备方法
JP2023536341A (ja) カルバメート化合物を含む経口用固形製剤及びその製造方法
HK40027115A (en) Solid dispersion
HK40030491A (en) High-strength oral taxane compositions and methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213780

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151111

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1213780

Country of ref document: HK